Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-11737
Eur J Clin Microbiol Infect Dis 1999 Nov 01;1811:827-9. doi: 10.1007/s100960050410.
Show Gene links Show Anatomy links

In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics.

Giacometti A , Cirioni O , Barchiesi F , Fortuna M , Scalise G .


???displayArticle.abstract???
The in vitro activity of ranalexin alone and in combination with other cationic peptides, macrolides, rifampin, and rifabutin was investigated against a clinical isolate of Cryptosporidium parvum. Susceptibility tests were performed by inoculation of the isolate onto cell monolayers and determining the parasite count after 48 h of incubation at 37 degrees C. Antibiotic-free cultures were used as controls in the study. Ranalexin showed low anticryptosporidial activity: it suppressed the growth of parasites by > or = 40% at 50 microM. Ranalexin showed enhanced activity when it was combined with noninhibitory concentrations of other compounds: a 74.4-94.1% reduction in the number of parasites was observed when ranalexin 50 microM was combined with magainin II 50 microM, indolicidin 50 microM, clarithromycin 8 mg/l, azithromycin 8 mg/l, rifampin 8 mg/l, and rifabutin 8 mg/l. The results suggest that ranalexin may be effective in inhibiting Cryptosporidium parvum growth in vitro upon combination with other peptides and hydrophobic antibiotics.

???displayArticle.pubmedLink??? 10614961
???displayArticle.link??? Eur J Clin Microbiol Infect Dis


Species referenced: Xenopus
Genes referenced: magainins